These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 25785246)

  • 1. Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas.
    Penman CL; Faulkner C; Lowis SP; Kurian KM
    Front Oncol; 2015; 5():54. PubMed ID: 25785246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies for targeting BRAF in human cancer.
    Pratilas CA; Solit DB
    Rev Recent Clin Trials; 2007 May; 2(2):121-34. PubMed ID: 18473997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
    Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.
    Dasgupta T; Haas-Kogan DA
    Front Oncol; 2013; 3():110. PubMed ID: 23717811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
    Halilovic E; Solit DB
    Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting
    Burkart J; Owen D; Shah MH; Abdel-Misih SRZ; Roychowdhury S; Wesolowski R; Haraldsdottir S; Reeser JW; Samorodnitsky E; Smith A; Konda B
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1035-1040. PubMed ID: 30181415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution.
    Di Nunno V; Gatto L; Tosoni A; Bartolini S; Franceschi E
    Front Oncol; 2022; 12():1067252. PubMed ID: 36686797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.
    Lo HW
    Curr Cancer Drug Targets; 2010 Dec; 10(8):840-8. PubMed ID: 20718706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].
    Lopes JP; Fonseca E
    Acta Med Port; 2011 Dec; 24 Suppl 4():855-68. PubMed ID: 22863493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [BRAF gene mutation in thyroid cancer].
    Kopczyńska E; Junik R; Tyrakowski T
    Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications.
    Lhermitte B; Wolf T; Chenard MP; Coca A; Todeschi J; Proust F; Hirsch E; Schott R; Noel G; Guerin E; Reita D; Chammas A; Salmon A; Martin S; Dontenwill M; Entz-Werlé N
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.
    Tan JY; Wijesinghe IVS; Alfarizal Kamarudin MN; Parhar I
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33557011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.
    Tang KT; Lee CH
    J Chin Med Assoc; 2010 Mar; 73(3):113-28. PubMed ID: 20230995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives.
    Crispo F; Notarangelo T; Pietrafesa M; Lettini G; Storto G; Sgambato A; Maddalena F; Landriscina M
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
    Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
    Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.